TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18316700

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Stereoscopic fundus photographs (FP)
Number of subjects: 263
Study: 15772062

Group type: EXPERIMENTAL
Intervention: Exercise training on cycle ergometers three times per week for 15 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 53
Study: 12502214

Group type: EXPERIMENTAL
Intervention: Gallstones present
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Impacted stones
Number of subjects: 1173
Study: 10048679

Group type: EXPERIMENTAL
Intervention: Azithromycin suspension for 5 days
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate for 10 days (for those <5 years)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate suspension (for those >=5 years)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Healthy control children (no treatment)
Number of subjects: 168
Study: 7670281

Group type: EXPERIMENTAL
Intervention: Basal XI HTF (modified HTF containing EDTA and glutamine but devoid of glucose and phosphate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal HTF (HTF containing EDTA and glutamine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular HTF
Number of subjects: 0
Study: 2289214

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg twice a day for 21 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 20
Study: 383024

Group type: EXPERIMENTAL
Intervention: IV salbutamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: IV aminophylline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0
Study: 30620389

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 4
Study: 27624622

Group type: COMPARATOR
Intervention: Neladenoson bialanate 30 mg single dose
Number of subjects: 42

Group type: COMPARATOR
Intervention: Neladenoson bialanate 10 mg for 7 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Neladenoson bialanate 20 mg for 7 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 42
Study: 26251661

Group type: EXPERIMENTAL
Intervention: Psycho education during three sessions of one-hour
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no psycho education)
Number of subjects: 60
Study: 24355056

Group type: EXPERIMENTAL
Intervention: DOiT program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 20
Study: 20682612

Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine (NAC) with intravenous hydration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous hydration only
Number of subjects: 40
Study: 19246588

Group type: EXPERIMENTAL
Intervention: Prandial strategy (three premeal doses of insulin lispro targeting 2-h postprandial blood glucose <7.5 mmol/l)
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Basal strategy (NPH twice daily or insulin glargine once daily targeting fasting/premeal blood glucose <6.7 mmol/l)
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Prandial strategy
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Basal strategy
Number of subjects: 1115
Study: 16893526

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Taste-matched placebo
Number of subjects: 73
Study: 15146410

Group type: EXPERIMENTAL
Intervention: Full-dosage etanercept (25 mg twice weekly) plus anakinra (100 mg/day)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Etanercept only (25 mg twice weekly)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Half-dosage etanercept (25 mg once weekly) plus anakinra (100 mg/day)
Number of subjects: 244
Study: 11260442

Group type: EXPERIMENTAL
Intervention: Didactic alcohol education programme
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Didactic input plus skills-based training
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (traditional medical school)
Number of subjects: 154
Study: 9408807

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg once daily for 15 days) with terfenadine (60 mg twice daily for 8 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Terfenadine (60 mg twice daily for 8 days) alone
Number of subjects: 12
Study: 7969324

Group type: EXPERIMENTAL
Intervention: Perioperative nutritional support (intravenous solution enriched with 35% branched-chain amino acids, dextrose, and lipid emulsion for 14 days)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Perioperative nutritional support
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study: 3297129

Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid 20 mg/d if marrow blasts ≤ 5% or cytosine arabinoside 10 mg/d subcutaneously on 6 d/week if marrow blasts 6-30%, retinoic acid added after 12 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group receiving conventional supportive therapy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid with cytosine arabinoside in non-sideroblastic patients with ≤ 5% blasts
Number of subjects: 98
Study: 31972315

Group type: COMPARATOR
Intervention: YKL‐40 percentile category 91‐100%
Number of subjects: 94665
Study: 30022571

Group type: EXPERIMENTAL
Intervention: isCGM group (26 participants, blinded for SMBG, insulin dosing based on isCGM)
Number of subjects: 46

Group type: COMPARATOR
Intervention: SMBG group (20 participants, blinded for isCGM, insulin dosing based on SMBG)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: isCGM group (26 participants)
Number of subjects: 46
Study: 27222271

Group type: EXPERIMENTAL
Intervention: CEP-26401 (0.02 to 5 mg single dose; 0.02 to 0.5 mg once daily multiple dosing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26476367

Group type: EXPERIMENTAL
Intervention: bivalent OPV (bOPV)
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: IPV
Number of subjects: 975

Group type: COMPARATOR
Intervention: f-IPV
Number of subjects: 975
Study: 23850070

Group type: EXPERIMENTAL
Intervention: Scapular repositioning with active cervical rotation technique in addition to conventional physiotherapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional physiotherapy (microwave diathermy, submaximal isometrics, and ergonomic advice)
Number of subjects: 23
Study: 20504165

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (7vPnC) with 1 mg of CPG 7909 adjuvant
Number of subjects: 97

Group type: COMPARATOR
Intervention: Phosphate-buffered saline (control)
Number of subjects: 97
Study: 18357436

Group type: EXPERIMENTAL
Intervention: VTEVC‐compensation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: VTplet‐compensation
Number of subjects: 9

Group type: COMPARATOR
Intervention: No compensation
Number of subjects: 9
Study: 16670616

Group type: EXPERIMENTAL
Intervention: Somatostatin 62.5 microg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Somatostatin 125 microg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Somatostatin 250 microg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12651666

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 20
Study: 10648327

Group type: EXPERIMENTAL
Intervention: Dopamine, 2 microg. kg(‐1). min(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo IV infusion (Control)
Number of subjects: 20
Study: 9289428

Group type: EXPERIMENTAL
Intervention: Pregnancy Induced Hypertension (PIH) group
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (healthy patients)
Number of subjects: 63
Study: 1900223

Group type: EXPERIMENTAL
Intervention: Presence of coronary collateral vessels (group A, n = 51)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Absence of coronary collateral vessels (group B, n = 74)
Number of subjects: 125
Study: 6094448

Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g intravenous at the induction of anaesthesia, the beginning of the resection, 4 and 8 h later (Group A)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g intravenous at the induction of anaesthesia, the beginning of the resection, 4 and 8 h later, associated with ornidazole or metronidazole 0.5 g intravenous at the induction of anaesthesia and 0.5 g intravenous with the last injection of cefotaxime (Group B)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Cefotaxime following the same regimen as groups A and B and metronidazole orally 0.5 tds 3 days before surgery (Group C)
Number of subjects: 217
Study: 31124023

Group type: EXPERIMENTAL
Intervention: Moderated private Facebook group (N=72)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Self-directed intervention materials without additional support (N=31)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups (N=103)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Facebook group (N=72)
Number of subjects: 103
Study: 28089142

Group type: EXPERIMENTAL
Intervention: Low mean arterial pressure (MAP) (40‐60 mmHg; n = 5)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High mean arterial pressure (MAP) (60‐80 mmHg; n = 5)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional monitoring of rSO2 by NIRS
Number of subjects: 10
Study: 25830503

Group type: EXPERIMENTAL
Intervention: Web-based HealthyPast50 program
Number of subjects: 278

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 278
Study: 23475451

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (N=97) including education about blood‐borne diseases and referrals for testing and vaccinations
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Experimental intervention (N=105) providing on‐site infectious disease education, screening of risk level, pretest counseling, testing for HIV and hepatitis B and C, vaccination for hepatitis A and B, and personalized risk‐reduction counseling
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 202
Study: 21176079

Group type: EXPERIMENTAL
Intervention: BCG maintenance therapy (81 mg, intravesically instilled once weekly for 6 weeks as induction therapy, followed by three once-weekly instillations at 3, 6, 12 and 18 months)
Number of subjects: 116

Group type: COMPARATOR
Intervention: BCG non-maintenance therapy (81 mg, intravesically instilled once weekly for 6 weeks)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Epirubicin therapy (40 mg, intravesically instilled nine times)
Number of subjects: 116
Study: 19958865

Group type: EXPERIMENTAL
Intervention: Restrictive filling pattern in patients with atrial fibrillation
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Restrictive filling pattern in patients with sinus rhythm
Number of subjects: 880

Group type: COMPARATOR
Intervention: Patients in sinus rhythm
Number of subjects: 880
Study: 17413839

Group type: EXPERIMENTAL
Intervention: 40 mg isoflavones
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: 80 mg isoflavones
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo (0 mg isoflavones)
Number of subjects: 203
Study: 15225827

Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 11407675

Group type: EXPERIMENTAL
Intervention: Multiband ligation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sclerotherapy combined with band ligation
Number of subjects: 0
Study: 9644639

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 205
Study: 7944005

Group type: EXPERIMENTAL
Intervention: Rapid release theophylline
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sustained release theophylline
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3266333

Group type: EXPERIMENTAL
Intervention: Bromocriptine therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no bromocriptine)
Number of subjects: 54
Study: 30281551

Group type: EXPERIMENTAL
Intervention: Patient screening activities
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Patient contact activities
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Performing procedures
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Physician contact activities
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Other activities
Number of subjects: 8
Study: 28399844

Group type: EXPERIMENTAL
Intervention: Triple marker screening followed by patient and provider education
Number of subjects: 1819

Group type: EXPERIMENTAL
Intervention: Triple marker screening, education, and clinical pharmacist-led CKD and BP management program
Number of subjects: 1819

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1819
Study: 25631707

Group type: EXPERIMENTAL
Intervention: Group setting intervention (n=77)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Individual setting intervention (n=78)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Stress management education (SME)
Number of subjects: 425
Study: 23395189

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 134
Study: 21689775

Group type: EXPERIMENTAL
Intervention: Tiotropium (Tio) plus transdermal tulobuterol (Tulo) 18 μg once daily plus 2 mg once daily for 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Tiotropium (Tio) 18 μg once daily for 4 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tiotropium (Tio) plus transdermal tulobuterol (Tulo)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Tiotropium (Tio)
Number of subjects: 16
Study: 19381345

Group type: EXPERIMENTAL
Intervention: Empirical efficiency maximization method for covariate adjustment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard locally efficient estimators
Number of subjects: 0
Study: 16987311

Group type: EXPERIMENTAL
Intervention: Pay-for-performance (P4P) programs
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: 26-item survey measuring key features of P4P programs
Number of subjects: 798
Study: 12691930

Group type: EXPERIMENTAL
Intervention: Vapreotide
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study: 11467343

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) infusion of α-Lipoic acid (LA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of α-Lipoic acid (LA)
Number of subjects: 0
Study: 9663825

Group type: EXPERIMENTAL
Intervention: CDP571 (5 mg/kg, single intravenous infusion)
Number of subjects: 15
Study: 8245892

Group type: EXPERIMENTAL
Intervention: 400 mg of acyclovir twice daily
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Episodic treatment (ES)
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Open-label acyclovir suppressive therapy
Number of subjects: 1146
Study: 3516408

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) nasal spray, dosage 1 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 29470365

Group type: EXPERIMENTAL
Intervention: Chain BP
Number of subjects: 13

Group type: COMPARATOR
Intervention: Plate BP
Number of subjects: 13
Study: 29509516

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 27898164

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg IV)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 138
Study: 25842461

Group type: EXPERIMENTAL
Intervention: SRP combined with prescription-tray application of 1.7% hydrogen peroxide gel and doxycycline for 2 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: SRP combined with prescription-tray application of 1.7% hydrogen peroxide gel
Number of subjects: 61

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 61
Study: 22678317

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILS‐C)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 65
Study: 20124186

Group type: EXPERIMENTAL
Intervention: Enzastaurin 500 mg/d (1,125 mg loading dose, day 1)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Lomustine (100 to 130 mg/m2, day 1)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Enzastaurin
Number of subjects: 266

Group type: COMPARATOR
Intervention: Lomustine
Number of subjects: 266
Study: 19102734

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 555

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 555
Study: 16186525

Group type: EXPERIMENTAL
Intervention: Elastic stockings + Intermittent pneumatic compression (IPC)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Elastic stockings (ES) alone
Number of subjects: 151
Study: 12444284

Group type: EXPERIMENTAL
Intervention: Minimal transurethral resection of the prostate followed by bladder neck incision
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard transurethral resection of the prostate (TURP)
Number of subjects: 40
Study: 10081852

Group type: COMPARATOR
Intervention: Mitomycin C (40 mg)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: BCG (120 mg, Danish strain 1331)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Second line BCG
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Second line Mitomycin C
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 261

Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 261
Study: 7769899

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 1680
Study: 2349137

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine 25 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 665568

Group type: EXPERIMENTAL
Intervention: 14.2 g of hemicellulose supplement per subject per day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 14.2 g of cellulose supplement per subject per day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 14.2 g of pectin supplement per subject per day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 14.2 g of pectin plus 1.3 g of zinc
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 14.2 g of pectin plus 9.3 g of zinc
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 4.2 g of pectin plus 1.3 g of zinc
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 4.2 g of pectin plus 9.3 g of zinc
Number of subjects: 19
Study: 31324132

Group type: EXPERIMENTAL
Intervention: Computer-aided detection software
Number of subjects: 120
Study: 31845226

Group type: EXPERIMENTAL
Intervention: Deep Acupuncture (DA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Shallow Acupuncture (SA)
Number of subjects: 30
Study: 27853058

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 917

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 917

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 917

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 917
Study: 25060913

Group type: EXPERIMENTAL
Intervention: Exercise condition (n=16)
Number of subjects: 26
Study: 24050737

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Glimepiride (2 mg)
Number of subjects: 33
Study: 20878653

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (5 mL of liquid fibrin sealant sprayed before drains insertion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no fibrin sealant)
Number of subjects: 30
Study: 19338151

Group type: EXPERIMENTAL
Intervention: Ginaton (0.5 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (routine CPB and cold St. Thomas' cardioplegia perfusion)
Number of subjects: 20
Study: 17403437

Group type: EXPERIMENTAL
Intervention: Ring pessary
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Gellhorn pessary
Number of subjects: 134
Study: 15488063

Group type: EXPERIMENTAL
Intervention: Cardiff paediatric laryngoscope blade
Number of subjects: 78

Group type: COMPARATOR
Intervention: Miller laryngoscope blade
Number of subjects: 78

Group type: COMPARATOR
Intervention: Macintosh laryngoscope blade
Number of subjects: 78
Study: 12603357

Group type: EXPERIMENTAL
Intervention: Multimedia software package 'All About Nocturnal Enuresis'
Number of subjects: 270

Group type: COMPARATOR
Intervention: Written leaflets containing the same information
Number of subjects: 270
Study: 10201475

Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg/h continuous infusion after an initial 100-microg bolus)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7781346

Group type: EXPERIMENTAL
Intervention: 100 mg methylprednisolone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 500 mg methylprednisolone
Number of subjects: 150
Study: 2150527

Group type: EXPERIMENTAL
Intervention: 100 mg GBR 12909
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 200 mg GBR 12909
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 300 mg GBR 12909
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 50 mg GBR 12909
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 150 mg GBR 12909
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GBR 12909 (various doses)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GBR 12909
Number of subjects: 8
Study: 376079

Group type: EXPERIMENTAL
Intervention: Brompton mixture (containing morphine, cocaine, ethyl alcohol, syrup BP, and chloroform water) administered orally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine alone in a flavoured aqueous solution administered orally
Number of subjects: 0